NEW YORK ( TheStreet) -- Shares of Human Genome Sciences Inc (Nasdaq: HGSI) were gapping down Wednesday morning with an open price 13.6% lower than Tuesday's closing price. The stock closed at $12.73 Tuesday and opened today's trading at $11. The average volume for Human Genome Sciences has been 5.3 million shares per day over the past 30 days. Human Genome Sciences has a market cap of $2.6 billion and is part of the health care sector and drugs industry. Shares are down 46.7% year to date as of the close of trading on Tuesday. Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. TheStreet Ratings rates Human Genome Sciences as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally weak debt management, disappointing return on equity and weak operating cash flow. You can view the full Human Genome Sciences Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.